Skip to content
AnalystLens

Leidos Holdings 8-K Report, Financial Results (Jul 30, 2024)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed July 30, 2024
Period End
July 30, 2024
Security
LDOS
In the record · 2016–202610-K1210-Q338-K130

LDOS filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 130 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Aug ’17Aug ’17
  2. Leadership change8-K · Mar ’20Mar ’20
  3. Leadership change8-K · Feb ’22Feb ’22
  4. Material agreement8-K · Oct ’26Oct ’26

Summary

Summary of the 8-K filed July 30, 2024. Cited figures are marked; the original filing is the authoritative source.

Leidos Holdings, Inc. reported second-quarter fiscal 2024 results for the quarter ended June 28, 2024, with revenues of $4.13 billiona, up 8% year-over-year, and net income of $324 million, or $2.37 per diluted share, compared with $210 million, or $1.50 per diluted share, a year earlier.

Adjusted EBITDA (non-GAAP) was $559 millionb, up 33%, at a record 13.5% margin, and non-GAAP diluted EPS was $2.63, up 46%. Management attributed the higher profitability to increased volumes, higher earned incentives on managed health services, and improved cost control. Health & Civil was the main driver, with operating income margin of 24.3% versus 13.0% a year earlier.

Commercial & International was the weak spot, with an operating margin of (2.0)%, which the filing attributes to UK contract adjustments. Cash performance was strong. Operating cash flow was $374 millionc and free cash flow (non-GAAP) was $351 million, with an operating cash flow conversion ratio of 116% and a non-GAAP free cash flow conversion ratio of 98%.

Days sales outstanding was 58, a 1-day improvement. The company returned $165 milliond to shareholders in the quarter, including $114 million in share repurchases and $51 million in dividends. Net bookings were $4.0 billion, a book-to-bill ratio of 1.0 for the quarter and 1.1 for the trailing twelve months, and backlog ended the quarter at $36.5 billion, of which $8.0 billion was funded.

Leidos raised its fiscal 2024 guidance for revenues to $16.1 to $16.4 billion (from $16.0 to $16.4 billion), adjusted EBITDA margin to approximately 12% (from mid-to-high 11%), and non-GAAP diluted EPS to $8.60 to $9.00 (from $8.40 to $8.80). Operating cash flow guidance was unchanged at approximately $1.3 billion. The board declared a quarterly dividend of $0.38 per share, payable September 27, 2024.

Key Highlights

  1. Revenue of $4.13 billion, up 8% year-over-year, driven by demand across all customer segments, especially managed health services.
  2. Net income of $324 million ($2.37 per diluted share), up 54% and 58% year-over-year respectively; net income margin of 7.8% versus 5.5% a year earlier.
  3. Adjusted EBITDA of $559 million, up 33%, with a record 13.5% margin; non-GAAP diluted EPS of $2.63, up 46%.
  4. Health & Civil revenues rose 22% to $1.26 billion, with operating income margin of 24.3% versus 13.0%, reflecting managed health services volumes and better incentive performance.
  5. Commercial & International operating margin was (2.0)% due to UK contract adjustments, compared with 6.2% a year earlier.
  6. Operating cash flow of $374 million and free cash flow (non-GAAP) of $351 million; DSO improved to 58 days.
  7. Fiscal 2024 guidance raised for revenues ($16.1 to $16.4 billion), adjusted EBITDA margin (approximately 12%), and non-GAAP diluted EPS ($8.60 to $9.00).

Frequently Asked Questions

  1. How did Leidos perform financially in the second quarter of fiscal 2024?

    Revenues were $4.13 billion, up 8% year-over-year. Net income was $324 million, or $2.37 per diluted share, compared with $210 million, or $1.50 per diluted share, in the prior-year quarter. Adjusted EBITDA was $559 million, up 33%, at a 13.5% margin, and non-GAAP diluted EPS was $2.63, up 46%.

  2. What drove the increase in profitability?

    The company attributed the higher profitability to increased volumes, higher earned incentives on managed health services, and improved cost control across the company. Health & Civil operating income margin rose to 24.3% from 13.0%, and Defense Systems margin improved to 6.9% from 4.5%.

  3. Which segment underperformed, and why?

    Commercial & International reported an operating margin of (2.0)%, compared with 6.2% in the prior-year quarter. The filing states that the decrease was driven by UK contract adjustments, and revenues within the segment rose 3% to $561 million.

  4. What is the company's financial position and capital return activity?

    As of June 28, 2024, Leidos had $823 million in cash and cash equivalents and $4.7 billion of debt. In the quarter it returned $165 million to shareholders, including $114 million in share repurchases and $51 million in dividends. The board declared a $0.38 per share dividend payable September 27, 2024, to holders of record on September 13, 2024.

  5. How did Leidos change its fiscal 2024 outlook?

    Revenue guidance was narrowed to $16.1 to $16.4 billion from $16.0 to $16.4 billion. Adjusted EBITDA margin guidance moved to approximately 12% from mid-to-high 11%, and non-GAAP diluted EPS guidance rose to $8.60 to $9.00 from $8.40 to $8.80. Operating cash flow guidance was unchanged at approximately $1.3 billion.